Detalles de la búsqueda
1.
A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis.
Pediatr Dermatol
; 41(2): 204-209, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38308453
2.
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data.
Pediatr Dermatol
; 39(2): 187-196, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35083774
3.
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.
Paediatr Drugs
; 26(2): 163-173, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38267692
4.
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
Adv Ther
; 40(1): 367-380, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36318387
5.
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.
Am J Clin Dermatol
; 24(5): 787-798, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37300760
6.
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis.
Dermatol Ther (Heidelb)
; 12(7): 1501-1533, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35596901
7.
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
Dermatol Ther (Heidelb)
; 11(4): 1357-1372, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34142350
8.
Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
J Clin Virol
; 44(4): 287-91, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19233722
9.
TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model.
Vaccine
; 27(3): 421-30, 2009 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-19013492
10.
C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.
Vaccine
; 25(16): 3228-32, 2007 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-17374422
11.
Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
Vaccine
; 25(29): 5378-89, 2007 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-17561317
12.
Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.
Vaccine
; 24(10): 1625-32, 2006 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-16243411
13.
A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.
Vaccine
; 21(25-26): 3706-12, 2003 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-12922101
Resultados
1 -
13
de 13
1
Próxima >
>>